Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Predicting Change in the Alzheimer’s Brain

October 6, 2015 11:15 am | by MIT News Office | News | Comments

MIT researchers are developing a computer system that uses genetic, demographic, and clinical data to help predict the effects of disease on brain anatomy. Read more...


Inspirion Receives FDA Approval for MorphaBond, an Opioid Analgesic

October 6, 2015 11:09 am | News | Comments

Inspirion Delivery Technologies LLC ("Inspirion") announced that the United States Food and Drug Administration (FDA) has approved MorphaBond (morphine sulfate) extended-release tablets, for oral use, CII. Read more...


3 Ways Viruses Have Changed Science for the Better

October 6, 2015 11:04 am | by University of California San Francisco | News | Comments

A virus is nature’s efficient little killer. It can invade a cell, take over its inner machinery, trick it into making more virus DNA and escape with a new posse of virus children (often killing the host in the process). Read more...


Researchers Identify New Gene Linked to Amyloid Beta Plaque Buildup in Alzheimer's Disease

October 6, 2015 10:53 am | by Indiana University | News | Comments

In a newly published study, a multi-institutional team led by scientists at the Indiana University School of Medicine have discovered an immune system gene associated with higher rates of amyloid plaque buildup in the brains of Alzheimer's patients and older adults at risk for the disease. Read more...


Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools

October 6, 2015 10:23 am | by Laura McKain, M.D., Medical Director, Pharmacovigilance; Tammy Jackson, Director, Preclarus Development, Clinical Innovation; Cindy Elko-Simms, M.D., Vice President, Pharmacovigilance, of PPD | Articles | Comments

Pharmaceutical companies must continuously monitor the safety of investigational products in development for adverse events that may be unexpected, occur at an increased frequency or severity, or result in an unexpected outcome. Ongoing safety signal detection leads to optimal patient protection and is essential to obtaining regulatory approval. Read more...


New Papers Discuss Details for Possible 'Exercise Pill'

October 6, 2015 8:30 am | by Ryan Bushey, Associate Editor | News | Comments

Test results are promising, but there is still a lot of work to be done to make this pill a reality. Read more...


Mixed-Up Cell Transportation Key Piece of ALS, Dementia Puzzle

October 6, 2015 8:00 am | by University of Toronto | News | Comments

Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment. Read more...


FDA Approves Alcon's Pre-loaded Intraocular Lens Delivery System

October 6, 2015 7:45 am | News | Comments

The device treats patients about to undergo cataract surgery. Read more...


Allergan, Humana Announce Research Partnership to Improve Health Outcomes

October 6, 2015 7:35 am | News | Comments

One of the collaboration's first projects focuses on Alzheimer's patients' caregiver burden. Read more...


Dengue Epidemics Linked to High Temps During Strong El Nino Season

October 6, 2015 7:30 am | by University of Pittsburgh | News | Comments

Dengue virus is transmitted by mosquitoes in the tropics and subtropics. Read more...


Cancer Test Predicts Treatment Outcomes

October 6, 2015 7:20 am | by University of Queensland | News | Comments

Researchers have announced a new tool in the fight against cancer. Read more...


NIH Establishes 4D Nucleome Research Centers and Organizational Hub at UC San Diego

October 5, 2015 11:19 am | by UC San Diego | News | Comments

Under its new 4D Nucleome Program, the National Institutes of Health (NIH) Common Fund has awarded three grants totaling more than $30 million over five years to multidisciplinary teams of researchers at University of California, San Diego. Read more...


Spark Therapeutics' Gene Therapy Shows Promising Trial Results

October 5, 2015 11:09 am | by Ryan Bushey, Associate Editor | News | Comments

Spark plans on filing for a biologics license application next year with the Food and Drug Administration. Read more...


FDA Approves Merck's Keytruda for Non-Small Cell Lung Cancer

October 5, 2015 10:15 am | News | Comments

Merck announced that the FDA has approved Keytruda (pembrolizumab) monotherapy, the company’s anti-PD-1 (programmed death receptor-1) therapy, at a dose of 2 mg/kg every three weeks, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy. Read more...


Stimulant Meds Safe, Effective for Children with ADHD, Congenital Heart Disease

October 5, 2015 10:07 am | by Cincinnati Children's Hospital Medical Center | News | Comments

A new study finds that children with congenital heart disease and ADHD can take stimulant medications without fear of significant cardiovascular side effects. Read more....



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.